175 related articles for article (PubMed ID: 21530364)
1. Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.
Cao S; Durrani FA; Toth K; Rustum YM; Seshadri M
Oral Oncol; 2011 Jun; 47(6):459-66. PubMed ID: 21530364
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
Fujita K; Sano D; Kimura M; Yamashita Y; Kawakami M; Ishiguro Y; Nishimura G; Matsuda H; Tsukuda M
Oncol Rep; 2007 Jul; 18(1):47-51. PubMed ID: 17549344
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.
Gyanchandani R; Sano D; Ortega Alves MV; Klein JD; Knapick BA; Oh S; Myers JN; Kim S
Oral Oncol; 2013 Aug; 49(8):761-70. PubMed ID: 23623402
[TBL] [Abstract][Full Text] [Related]
4. A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma.
Gyanchandani R; Ortega Alves MV; Myers JN; Kim S
Mol Cancer Res; 2013 Dec; 11(12):1585-96. PubMed ID: 24092775
[TBL] [Abstract][Full Text] [Related]
5. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Cao S; Durrani FA; Rustum YM
Clin Cancer Res; 2004 Apr; 10(7):2561-9. PubMed ID: 15073137
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
Bhattacharya A; Tóth K; Durrani FA; Cao S; Slocum HK; Chintala S; Rustum YM
Neoplasia; 2008 Aug; 10(8):857-65. PubMed ID: 18670644
[TBL] [Abstract][Full Text] [Related]
7. The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.
Clémenson C; Jouannot E; Merino-Trigo A; Rubin-Carrez C; Deutsch E
Invest New Drugs; 2013 Apr; 31(2):273-84. PubMed ID: 22810221
[TBL] [Abstract][Full Text] [Related]
8. Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models.
Koonce NA; Griffin RJ; Dings RPM
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29232825
[TBL] [Abstract][Full Text] [Related]
9. The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts.
Bozec A; Etienne-Grimaldi MC; Fischel JL; Sudaka A; Toussan N; Formento P; Milano G
Oral Oncol; 2011 May; 47(5):340-4. PubMed ID: 21421338
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model.
Bozec A; Sudaka A; Etienne-Grimaldi MC; Brunstein MC; Fischel JL; Milano G
Oral Oncol; 2011 Oct; 47(10):940-5. PubMed ID: 21862388
[TBL] [Abstract][Full Text] [Related]
11. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
Chintala S; Tóth K; Cao S; Durrani FA; Vaughan MM; Jensen RL; Rustum YM
Cancer Chemother Pharmacol; 2010 Oct; 66(5):899-911. PubMed ID: 20066420
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
Azrak RG; Cao S; Slocum HK; Tóth K; Durrani FA; Yin MB; Pendyala L; Zhang W; McLeod HL; Rustum YM
Clin Cancer Res; 2004 Feb; 10(3):1121-9. PubMed ID: 14871992
[TBL] [Abstract][Full Text] [Related]
13. Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.
Bozec A; Sudaka A; Fischel JL; Brunstein MC; Etienne-Grimaldi MC; Milano G
Br J Cancer; 2008 Jul; 99(1):93-9. PubMed ID: 18577994
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Kenmotsu H; Sugino T; Matsumura Y
Clin Cancer Res; 2010 Jan; 16(2):521-9. PubMed ID: 20068081
[TBL] [Abstract][Full Text] [Related]
15. Can 111In-RGD2 monitor response to therapy in head and neck tumor xenografts?
Terry SY; Abiraj K; Lok J; Gerrits D; Franssen GM; Oyen WJ; Boerman OC
J Nucl Med; 2014 Nov; 55(11):1849-55. PubMed ID: 25349221
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers.
Wu X; Jeong EK; Emerson L; Hoffman J; Parker DL; Lu ZR
Mol Pharm; 2010 Feb; 7(1):41-8. PubMed ID: 19958031
[TBL] [Abstract][Full Text] [Related]
17. EMMPRIN expression is required for response to bevacizumab therapy in HNSCC xenografts.
Newman JR; Helman EE; Safavy S; Zhang W; Rosenthal EL
Cancer Lett; 2009 Feb; 274(2):313-8. PubMed ID: 18990485
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models.
Lee FY; Covello KL; Castaneda S; Hawken DR; Kan D; Lewin A; Wen ML; Ryseck RP; Fairchild CR; Fargnoli J; Kramer R
Clin Cancer Res; 2008 Dec; 14(24):8123-31. PubMed ID: 19088027
[TBL] [Abstract][Full Text] [Related]
19. Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Bhattacharya A; Tóth K; Mazurchuk R; Spernyak JA; Slocum HK; Pendyala L; Azrak R; Cao S; Durrani FA; Rustum YM
Clin Cancer Res; 2004 Dec; 10(23):8005-17. PubMed ID: 15585636
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
